C-reactive protein and pentraxin-3 binding of factor H-like protein 1 differs from complement factor H: Implications for retinal inflammation by Swinkels, M. (Maurice) et al.
1SCiENTiFiC RePoRTs |  (2018) 8:1643  | DOI:10.1038/s41598-017-18395-7
www.nature.com/scientificreports
C-reactive protein and pentraxin-3 
binding of factor H-like protein 
1 differs from complement 
factor H: implications for retinal 
inflammation
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Perveen3,4, Selina McHarg3, Antonio Inforzato5,6, Anthony J. Day  1 & Simon J. Clark  3
Retinal inflammation plays a key role in the progression of age-related macular degeneration (AMD), 
a condition that leads to loss of central vision. The deposition of the acute phase pentraxin C-reactive 
protein (CRP) in the macula activates the complement system, thereby contributing to dysregulated 
inflammation. The complement protein factor H (FH) can bind CRP and down-regulate an inflammatory 
response. However, it is not known whether a truncated form of FH, called factor H-like protein 1  
(FHL-1), which plays a significant regulatory role in the eye, also interacts with CRP. Here, we compare 
the binding properties of FHL-1 and FH to both CRP and the related protein pentraxin-3 (PTX3). We find 
that, unlike FH, FHL-1 can bind pro-inflammatory monomeric CRP (mCRP) as well as the circulating 
pentameric form. Furthermore, the four-amino acid C-terminal tail of FHL-1 (not present in FH) plays a 
role in mediating its binding to mCRP. PTX3 was found to be present in the macula of donor eyes and 
the AMD-associated Y402H polymorphism altered the binding of FHL-1 to PTX3. Our findings reveal 
that the binding characteristics of FHL-1 differ from those of FH, likely underpinning independent 
immune regulatory functions in the context of the human retina.
Complement factor H (FH) is an ~155 kDa serum glycoprotein that is mainly synthesized in the liver and is 
one of the central regulators of the complement system, a protein cascade that plays a crucial role in host innate 
immunity1. Activation of complement, via classical, lectin or alternative pathways, leads to a local inflammatory 
response, generation of membrane attack complexes (MAC) that cause cell lysis, and labels unwanted cells and 
debris for uptake and disposal by phagocytes; irrespective of how complement is activated, it is the alternative 
pathway that amplifies the response. As such, the activation and amplification of complement is tightly regulated 
by a series of cell surface complement regulators including decay accelerating factor (DAF, or CD55), mem-
brane bound co-factor protein (MCP, or CD46), and MAC-inhibitory protein (MAC-IP, or CD59). However, in 
the case of extracellular matrix structures, including basement membranes, none of these regulators is present 
and these rely on the recruitment of soluble complement regulators, such as FH, from the blood. Comprising 
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twenty complement control protein (CCP) domains (see Fig. 1A), FH anchors to surfaces primarily through its 
CCP6-8 and CCP19-20 regions2, where it can act as a negative regulator of the alternative pathway; e.g. by being a 
co-factor for complement factor I (FI) that cleaves deposited C3b into inactive C3b (iC3b) thereby down regulat-
ing the complement response1. A 49 kDa truncated version of FH exists in plasma, termed factor H-like protein 
1 (FHL-1), which arises from alternative splicing of the FH gene (CFH), and is identical to FH for the first seven 
CCPs before terminating in a unique four amino acid tail (Fig. 1A)3,4. It should be noted that smaller sizes are 
Figure 1. FHL-1, but not FH, binds to both monomeric and pentameric CRP. (A) Schematic representations of 
the FH proteins used in this study and the positions of CRP and PTX3 binding sites on FH/FHL-1; PTX3 binds 
through both its N- and C-terminal domains1,28. (B–F) A series of FH-based proteins were investigated for 
binding to immobilized monomeric CRP (mCRP) or pentameric CRP (pCRP) in plate assays: (B) Full-length 
FH from human plasma; (C,D), binding of the CCP6-8 402Y and 402 H variants to mCRP (C) and pCRP  
(D); (E,F), binding of the FHL-1 402Y and 402 variants to mCRP(E) and pCRP (F). (G) The maximum binding 
values for CCP6-8, FHL-1, and FH are re-plotted from the experiments in (B–F) to highlight the significant 
effect of the Y402H polymorphism; here paired Student’s t tests were run on selected data as shown (*p < 0.05; 
**p < 0.01, *****p < 0.00001). All data (mean ± SEM) are combined from two identical experiments 
performed in quadruplicate (n = 8).
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often quoted for FHL-1, but these are likely to represent the truncated N-terminal CCP1-5 tryptic fragment of 
FH (37 kDa)3,4. Furthermore, CCP containing proteins all run at lower apparent molecular weights when run on 
reduced gels5. Despite lacking the CCP19-20 domains and being present in plasma at lower concentrations than 
the full-length FH protein (30–50 vs 200–800 μg/ml)6, FHL-1 is able to regulate complement on surfaces to which 
it binds via its CCP67 domain, depending on the presence of suitable anchoring ligands7.
FH and FHL-1 anchor to surfaces through interactions with charged molecules such as the glycosaminogly-
can (GAG) chains of proteoglycans and, in the case of FH, also sialic acids7–9. The GAGs heparan sulfate (HS) 
and dermatan sulfate (DS) play a significant role in FH binding to cell surfaces and to extracellular matrices 
such as the glomeruli basement membrane in the human kidney and Bruch’s membrane in the human eye2,10. 
Indeed, the specificity of FH for patterns of sulfated GAGs is such that the CCP6-8 and 19–20 regions can differ-
entially regulate the binding to host tissues, i.e. depending on the population/composition of GAGs expressed 
therein2,8,11–13. This is highlighted by mutations in the CCP6-8 or CCP19-20 regions of FH impairing complement 
regulation in a tissue-specific manner. For example, a common polymorphism in CFH, (Y402H) that leads to a 
histidine replacing a tyrosine residue in CCP7 of both FH and FHL-1 (at residue 384 or 402 in the mature and 
pre-protein, respectively)3,14, affects the capacity of this anchoring domain to bind HS and DS in Bruch’s mem-
brane in the human eye2,10,15; however, it does not affect binding to the glomeruli basement membrane in the 
kidney, since the latter is mediated by the CCP19-20 region. Furthermore, given that FHL-1 contains only a sin-
gle GAG-interaction site (in CCPs6-7), and that this protein is the major factor H species present on the human 
Bruch’s membrane7, the Y402H polymorphism has the potential to have a significant impact on FHL-1 binding 
and thus regulation of complement activation. Indeed, the Y402H polymorphism is strongly associated with an 
increased risk of age-related macular degeneration (AMD)16,17, the leading cause of blindness in the developed 
world. A hallmark feature of AMD is complement dysregulation in the proximity of Bruch’s membrane that forms 
part of the outer blood-retinal barrier along with the retinal pigment epithelium (RPE), separating the neurosen-
sory retina from the blood supply in the choroid.
AMD is characterized by complement driven inflammation in the central retina (macula) leading to accu-
mulation of particulate material (termed drusen), cellular damage and the associated loss of central vision16. 
A number of markers of inflammation and complement activation are found deposited in and around Bruch’s 
membrane during the early stages of disease, including the acute phase, soluble pattern recognition molecule 
(sPRM), C-reactive protein (CRP)18. CRP is a short pentraxin that can activate complement via the classical 
and lectin pathways, thereby promoting opsonization and phagocytosis of apoptotic and necrotic cells1. It cir-
culates in blood as a non-covalent, non-inflammatory, pentamer (pCRP), which however dissociates into a 
pro-inflammatory monomer (mCRP) upon binding to certain surfaces19. Dissociation of the pentamer may also 
occur under particular pathogenic conditions, including absence of Ca2+, low pH and high urea concentrations 
(reviewed in19). FH inhibits CRP-mediated complement activation through its binding to the monomeric form of 
CRP via CCPs6-8 and CCPs16-2020–24, but does not interact with pCRP25. Individuals homozygous for the Y402H 
polymorphism in CFH have been found to have higher levels of CRP in the choroid at the back of the eye26, and 
interestingly the AMD-associated 402H form of FH has been shown to have reduced binding to mCRP20 and is 
less able to inhibit the inflammatory effects of mCRP in RPE cells27. Another inflammation-associated pentraxin 
that has been linked with complement activation is PTX3, where FH is known to bind this long pentraxin via its 
CCP6-8 (via CCP7) and CCP19-20 regions1,28; PTX3 enhances the interaction of FH with apoptotic cells leading 
to their increased opsonization with iC3b28. However, unlike CRP27, neither the plasma levels of PTX3 nor its 
gene expression in the RPE/choroid correlate with AMD status29. In addition, the Y402H polymorphism does 
not affect FH binding to PTX328. Interestingly, however, PTX3 expression increases in cultured RPE stimulated 
with inflammatory cytokines29,30 or peroxidated lipids (i.e., 4-hydroxynonenal, 4-HNE), and genetic deficiency of 
PTX3 magnifies complement activation in an animal model of AMD, with increased C3a and IL-1β levels in the 
RPE, and enhanced accumulation of macrophages in the choroid31.
While the interactions of FH with CRP have been well studied, and interactions between FH and PTX3 are 
starting to be elucidated, very little is known about the binding characteristics of FHL-1 for either pentraxin. 
Furthermore, the contribution to ligand binding made by the unique C-terminal tail of FHL-1 is poorly under-
stood. Given the likelihood that FHL-1 plays a more significant role in complement regulation than previously 
thought, particularly in the human eye5, we have compared the binding of FH and FHL-1 to both CRP and PTX3, 
investigated the effect of the AMD-associated Y402H polymorphism on these interactions, and investigated 
whether the FHL-1 tail contributes to binding.
Results
FHL-1 binding to CRP. To investigate the binding properties of FHL-1 for CRP we first validated our solid 
phase binding assays by using full length FH in the fluid phase and either mCRP or pCRP immobilized onto 
the surface. Here we found that FH bound mCRP, but did not bind pCRP (Fig. 1B) in agreement with previous 
studies25,27. In order to assess the effect of the AMD-associated Y402H polymorphism on FH binding to CRP 
we utilized our CCP6-8 recombinant proteins so that we could study this polymorphic region in isolation (i.e. 
in the absence of the secondary binding site for CRP at the C-terminal end of FH)21. We found that there was 
significantly less binding of the AMD-associated 402H variant than the 402Y form of CCP6-8 to immobilized 
mCRP (Fig. 1C,G), which is consistent with previous studies20. However, these truncated recombinant proteins 
also bound to pCRP (Fig. 1D,G), a phenomenon not shared with the full-length protein (Fig. 1B,G), suggesting 
interactions with the exposed N- or C- terminal regions of CCPs 6 and 8, respectively. Given that FHL-1 also has 
a largely exposed C-terminal face on CCP7 (see Fig. 1A), it seemed possible that FHL-1 might also recognize both 
forms of CRP. Indeed, when we analyzed the 402Y and 402 H variants of FHL-1 a clear binding was observed to 
both mCRP and pCRP (Fig. 1E,F), where the 402 H form of FHL-1 bound significantly less well to monomeric 
and pentameric CRP (Fig. 1G). SDS-PAGE verified that the differences in binding of the 402H and 402Y variants 
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were not due to differences in the concentrations (or purity) of the protein preparations used (see Figure S1). 
Interestingly, FHL-1 (402Y) is a relatively poor competitor against FH binding to mCRP, presumably due to 
FHL-1 having only one mCRP binding site, while FH has two (see Figure S2).
Investigating the role of the FHL-1 C-terminal tail on CRP binding. After establishing that FHL-1 
bound to both immobilized mCRP and pCRP we then investigated whether the protein’s unique C-terminal tail 
conferred any effect on these interactions; for this purpose 402 H and 402Y forms of recombinant CCP67 pro-
teins with or without the four amino acid tail were used, where these preparations were validated by SDS-PAGE 
(Figure S3). Here we found that the tail had a positive influence on the binding of the 402Y form of CCP67 to 
mCRP (Fig. 2A), where the absence of the tail lead to a statistically significant reduction in the levels of detectable 
binding at 5 μg/ml and 10 μg/ml concentrations. This effect was not observed when the CCP67 402Y protein was 
tested with pCRP (Fig. 2B). No effect of the tail on the binding of the 402 H form of CCP67 to either mCRP or 
pCRP was observed (Fig. 2C,D).
FHL-1 binding to PTX3 and the role of its C-terminal tail. Given that PTX3 is known to interact with 
FH, in part via a binding site involving CCP728, we investigated whether, like CRP, it also binds to FHL-1. Here, 
we validated our solid phase binding assay by showing that the full-length FH interacted with immobilized PTX3 
(Fig. 3A), as was expected, and under the same conditions determined that FHL-1 also interacts with PTX3 
(Fig. 3B). The binding of FHL-1 to PTX3 appears to be of similar affinity to that of FHL-1 binding mCRP as evi-
denced in competition assays where ~50% inhibition of FHL-1 binding to immobilized mCRP is achieved with 
equimolar amounts of PTX3 (see Figure S4). Comparison of the 402H and 402Y variants of FHL-1 showed that 
the Y402H polymorphism causes a small but significant reduction in binding (p = 0.0025; by two-way ANOVA). 
The C-terminal tail of FHL-1 was found to make a significant contribution to the interaction with PTX3 in the 
context of both the 402Y and 402H variants (Fig. 3C–E).
Localization of CRP and PTX3 in non-AMD and AMD donor eyes. Since FHL-1 is able to interact 
with CRP and PTX3, and this truncated form of FH has been implicated as the predominant soluble comple-
ment regulator in Bruch’s membrane7, we stained for both of these related pentraxins in human eye tissues from 
donors with and without AMD. Consistent with previous studies18,26, CRP levels were found to be greater in AMD 
compared to non-AMD donor tissues, with staining associated with Bruch’s membrane and the underlying fenes-
trated blood vessels of the choriocapillaris (Fig. 4A). Staining for PTX3, which to our knowledge has not been 
thoroughly investigated in human donor eyes, revealed patches of positive immunoreactivity underneath Bruch’s 
membrane, in the intercapillary septa of the choriocapillaris and in the choroid (Fig. 4B,C). When the levels of 
PTX3 staining were quantitated (based on fluorescence intensity measurements), there was a slight trend towards 
Figure 2. Contribution of the FHL-1 C-terminal tail to CRP binding. Recombinant CCP67 proteins (i.e. 
402Y and 402 H variants with and without the 4-amino acid C-terminal tail of FHL-1) were used at a range 
of concentrations to determine their binding to immobilized monomeric CRP (mCRP) or pentameric CRP 
(pCRP) in plate assays. (A) Binding of the 402Y isoform of CCP67 constructs with/without tail to immobilized 
mCRP. Differences in binding at the two highest concentrations are statistically significant (Student T test, 
* = p < 0.05). (B) Binding of the 402Y isoform of CCP67 constructs with/without a tail to immobilized pCRP. 
(C) Binding of the 402 H isoform of CCP67 constructs with/without a tail to immobilized mCRP. (D) Binding 
of the 402 H isoform of CCP6-7 constructs with/without a tail to immobilized pCRP. Data (mean ± SEM) are 
combined from two identical experiments performed in quadruplicate (n = 8).
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increasing PTX3 levels in the AMD compared to non-AMD samples, however, this was not statistically significant 
for either the choroid (Fig. 5A) or choriocapillaris (Figure S5A). Furthermore, no statistically significant differ-
ence was seen for PTX3 levels when donor tissues were stratified on the basis of the Y402H polymorphism. Given 
the trend towards increasing PTX3 with AMD we stratified our samples for another high-risk genotype for AMD 
(SNPs in Chromosome 10 (Chr-10) around the ARMS2/HTRA1 genes) as well as a common AMD-protective 
genotype that includes the deletion of the CFHR1 and CFHR3 genes (Figs 5B–D and S5B–D). Neither showed a 
significant effect when analyzed by one-way ANOVA. The presence of a small number of luminal leukocytes that 
gave a strong fluorescent signal were detected in some of the donors, however this only occurred in five of the 18 
non-AMD donors, and four of the AMD cases, thus their presence did not alter the overall comparison of these 
samples.
Discussion
In this study we describe for the first time that FHL-1, a truncated form of FH, can bind to CRP and PTX3, pro-
totypes of the short and long pentraxins, respectively. FHL-1 was found to interact with both pro-inflammatory, 
monomeric, CRP and the circulating pentameric form, as well as the long pentraxin PTX3, which we have shown 
here to be present in the ECM of the choroid and choriocapillaris of eyes from AMD and non-AMD donors. 
Importantly, the 402Y variant of FHL-1 was found to bind significantly better to both CRP isoforms compared to 
the 402H variant, where as described below the altered binding to mCRP may be of particular relevance to AMD.
Figure 3. The C-terminal tail of FHL-1 contributes to PTX3 binding. In plate assays, PTX3 was used in the 
fluid phase to determine its binding to immobilized FH/FHL-1 proteins: (A) FH; (B) FHL-1: (C) CCP67 402Y 
( ± tail); and (D), CCP67 402 H ( ± tail). (E) The maximum binding values obtained from the experiments in 
(A–D) were re-plotted to highlight the significant effects between 402Y and 402 H forms of CCP67 ± tail; here 
statistical analysis (Student’s T test) compared pairs of data as shown (**p < 0.01, ****p < 0.0001). All data 
(mean ± SEM) are combined from two identical experiments performed in quadruplicate (n = 8) for FH and 
FHL-1, and three identical experiments performed in quadruplicate (n = 12) for CCP67 constructs. The binding 
curves in B are statistically different when analysed by two-way ANOVA, p = 0.0025, and the binding at the top 
three individual concentrations are statistically different where *p < 0.001 (Student’s T test).
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A unique feature of FHL-1 is the presence (at its C-terminus) of a 4 amino acid sequence on the exposed 
face of CCP7 that is not present in the full-length protein, or indeed some recombinant mimics of this pro-
tein23,24,28,32–34. Unlike FH, FHL-1 was found to bind pCRP in addition to mCRP, but the presence or absence of 
the tail did not have a major effect on binding when analyzed in the context of C-terminal CCP67 constructs that 
recapitulate the interaction of FHL-1 with CRP (Fig. 2). There was however a small, but statistically significant, 
reduction in the binding of the 402Y form of CCP67 with mCRP, when the tail was absent, suggesting that this 
sequence might play some minor role for this variant. Moreover, the tail was not implicated in the binding of 
the 402H variant of FHL-1 to mCRP or indeed the interaction of either variant of FHL-1 with pCRP, suggesting 
that other amino acids on the exposed face of CCP7 mediate these interactions. Interestingly, unlike CRP, the 
C-terminal tail of FHL-1 does appear to play an important role in its binding to PTX3 (Fig. 3C–E), where the 
absence of the SFTL sequence (in CCP67 constructs) led to a pronounced (and significant) reduction in the 
observed interaction: something that has not been reported previously. In addition, the AMD-associated Y402H 
polymorphism appeared to alter the binding of FHL-1 to PTX3 (where the 402Y allotype binds better than 
402H), although to a lesser extent than that described for CRP. This observation is inconsistent with a previous 
report indicating that the interaction of full length FH with PTX3 is not affected by the Y402H polymorphism28. 
However, it is likely that the interaction of FHL-1 with PTX3 is more sensitive to the Y402H polymorphism, 
because the polymorphism occurs in the only PTX3 binding site present in FHL-1, unlike in FH where a second-
ary binding site exists in CCPs19-20.
Given the interaction between FHL-1 and PTX3 we investigated the localization of this pentraxin in human 
donor eye tissues. PTX3 is known to bind FH at CCP7 and CCP19-2028, is able to modulate the classical and 
lectin pathways of complement35, and is expressed locally at sites of inflammation29, such as in RPE cells30,36. 
The C-terminal domain of PTX3 is homologous to CRP and binds CCP7, while the N-terminal domain binds 
CCP19-2028. PTX3 expression has been documented in a mouse model of AMD, where it co-localizes with FH 
in RPE and Bruch’s membrane. Furthermore, previous immunohistochemical staining of PTX-3 in the macula 
of an AMD patient detected this pentraxin in multiple layers of the retina, including Bruch’s membrane and the 
basement membrane of both RPE and choriocapillaris37. Consistent with previous reports, here we show that the 
PTX3 protein is present in the human macular tissue of AMD donors, however, for the first time, we documented 
the presence of this pentraxin in the macula of non-AMD donors. In this regard, PTX3 is well established to be 
expressed in inflammatory and inflammation-like conditions, and constitutive expression of the protein has only 
been described in cells from human amniotic membrane38 and in a mouse lymphatic endothelial cell line39. Our 
observation suggests a physiological role for PTX3 in the human macula, where the protein, locally and consti-
tutively made by the choroid and chorocapillaris endothelium (Fig. 4)37, might contribute to tissue homeostasis, 
Figure 4. Immunofluorescent staining of CRP and PTX3 in the macula of human donor eyes. Representative 
images of five (for CRP staining) and eighteen (PTX3) donor tissues are shown. (A) CRP staining in the macula 
region of non-AMD and AMD eyes (green) can be seen in the Bruch’s membrane (BrM) and choriocapillaris 
(CC), which underlie the retinal pigment epithelium (RPE); CRP staining was used as a control, given that it is 
known to accumulate in these locations during AMD. (B) Staining for PTX3 (green) can be seen in the stroma 
of the choriocapillaris (solid white arrows) and, in the case of AMD donors, cells within the blood vessels of the 
choroid also stain positive for PTX3 (open white arrow). (C) A higher magnification image of PTX3 staining 
(green) in the intercapillary septa of the choriocapillaris. In all cases blue nuclear staining is achieved with 
DAPI, and scale bars represent 10μm.
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e.g. by participating in the control of complement activation. In this respect, PTX3 has been recently proposed to 
act as an anchoring site for FH in Bruch’s membrane and RPE, where it limits complement-dependent inflamma-
tory response in a mouse model of oxidative stress-induced AMD31. This mechanism might also operate under 
physiological (non-AMD) conditions, to preserve integrity and functionality of the retinal tissue. Quantitation 
of staining revealed a trend towards higher PTX3 levels in AMD eyes and hinted at a possible relationship with 
AMD-associated SNPs, i.e. those responsible for the deletion of factor H related genes 1 and 3 (CFHR1-3) and 
the Y402H coding change (Figs 5 and S5); however, additional analysis with a greater number of donor samples 
would be required to investigate this further.
Dissociation of the pCRP into the pro-inflammatory mCRP is known to occur upon cell and matrix surfaces19, 
indicating that mCRP may be a tissue bound form while pCRP remains in circulation. Indeed, it has been shown 
recently that the majority of CRP found in processed human macula tissue sections is monomeric40, although 
undoubtedly non-deposited pCRP will be present within the lumen of blood vessels of the choroid in vivo. The 
exact mechanism of this dissociation is unclear, but may involve phospholipids such as lysophosphatidylcho-
line19,41. Bruch’s membrane acts as a biological filter to allow exchange of nutrients and waste products (but not 
cells or large macromolecules, i.e. above ~100 kDa) between the blood supply in the choroid and the cells in 
the neurosensory retina and its size exclusion properties are affected by age42,43. Therefore, the CRP present in 
Bruch’s membrane (Fig. 4) is most probably mCRP (~25 kDa), because of the likely lack of permeability to the 
larger pCRP (~125 kDa). Since mCRP is predominantly generated on cell surfaces19,41, it has been suggested 
that it is transported across Bruch’s membrane by way of cell membrane vesicles; thus, having the potential to 
become directly associated or trapped within this extracellular matrix. In this context, given that FHL-1 is the 
predominant form of complement regulator in BrM and intercapillary septa7,44 (FHL-1 can diffuse through the 
membrane while FH can not) and given that mCRP is also present in these locations18,22,45 (see Fig. 4A), it seems 
probable that FHL-1 will bind to mCRP and dampen any subsequent complement activation and the inflam-
matory response. This is unlike the binding of FHR-1 to mCRP, which has been found to promote complement 
activation46, because FHL-1 retains the capacity to act as a co-factor for the FI mediated cleavage of C3b, whereas 
Figure 5. Analysis of PTX3 staining in the choroid of human donor eyes stratified for AMD and AMD-risk 
genotypes. The average fluorescence intensity for PTX3 staining in the choroid of eighteen non-AMD and 
eighteen AMD donor tissues is shown. (A) PTX3 staining in the choroid of AMD eyes showed a trend towards 
increased levels when compared to age-matched control eyes, but did not reach statistical significance. (B) All 
donors (n = 36) were stratified based on the Y402H AMD-risk genotype and a trend was seen for increasing 
PTX3 staining when going from T/T (non-risk; 402Y/402Y homozygotes) to T/C to C/C (high risk; 402 H/402H 
homozygotes) genotypes. (C) PTX3 staining levels did not appear to correlate with chromosome 10 (Chr-10) 
non-risk (G/G) or AMD risk (A/T, A/A) genotypes. (D) The CFHR1/3 gene deletion (CFHR1/3 del) showed 
a trend towards a reduction in PTX3 staining with AMD-non-risk (GA, GG) genotypes, but did not to reach 
significance. Statistical analysis was performed using one-way ANOVA.
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FHR-1 does not. Our finding that the Y402H coding change reduces the capacity of FHL-1 to bind to mCRP 
(Fig. 1E) is important since it could explain how this AMD-associated polymorphism results in impaired comple-
ment regulation in or around BrM, leading to local inflammation that contributes to AMD disease progression.
Besides complement activation and inflammation, angiogenesis and vascular remodeling are well known phe-
nomena in AMD pathogenesis, particularly in wet AMD47. PTX3 inhibits FGF2-dependent angiogenesis48–50 and 
is also involved in matrix remodeling by crosslinking complexes of the polysaccharide hyaluronan covalently 
linked with so-called heavy chains, where this occurs during physiological processes (such as ovulation) and 
during inflammation51–53. Heavy chains are transferred onto hyaluronan from the protein inter-α-inhibitor (IαI), 
which is catalyzed by the inflammation-associated protein TNF-stimulated gene-6 (TSG-6)52; TSG-6 may also 
inhibit the anti-angiogenic properties of PTX350. Hyaluronan is present throughout the macula, e.g. being pres-
ent in the neurosensory retina, RPE, Bruch’s membrane and choroid54, however, the presence and localization of 
IαI and TSG-6 in this area of the eye has not been studied. We also observed PTX3 staining in yet-unidentified 
cells, which could be leukocytes (Fig. 4). PTX3 is locally produced by various cells of the immune system such 
as monocytes, macrophages, dendritic cells and neutrophils36,55; furthermore, endothelial cells, smooth muscle 
cells, epithelial cells and fibroblasts also express PTX336. Judging by the size and shape of the colocalizing cells 
(5-10 µm), these could be neutrophils, macrophages or monocytes. However, additional studies will be necessary 
to investigate this further.
The emergence of the pentraxin-family members CRP and PTX3 as potential mediators of complement in the 
eye could explain some of the molecular mechanisms of the disease. Genetic risk factors for AMD, such as the 
Y402H polymorphism, provide increasing evidence of the involvement of inflammatory processes in AMD in 
which FH and potentially FHL-1 may play a central role16,56–58. The Y402H polymorphism in the CFH gene results 
in an impaired ability to anchor FH/FHL-1 to cell surfaces and ECM via heparan sulfate10, as well as reduced 
binding to inflammatory mediators like CRP and, as demonstrated here, PTX320,27,59. Based on the data in this 
report, we hypothesize that the Y402H polymorphism reduces the ability of FH and FHL-1 to bind inflammatory 
mCRP and PTX3 (for FHL-1) in choroid (FH) and Bruch’s membrane (FHL-1). As a result, ECM structures like 
Bruch’s membrane will be insufficiently protected from inflammation and this would contribute to AMD patho-
genesis. In addition to inflammatory processes, both CRP and PTX3 affect angiogenesis and vascular remodeling. 
PTX3 may inhibit angiogenesis in some cases48,49, which is affected by the PTX3 binding protein TSG-650. At the 
same time, mCRP is able to induce CXCL8 and CCL2 expression in cultured RPE cells, cytokines which are both 
highly involved in choroidal neovascularization in AMD60,61. FH has been shown to inhibit this mCRP-induced 
expression in RPE cells27.
Our work indicates that the functional activities of FHL-1 are unlikely to simply replicate those of FH, and 
these proteins must be considered separately to get a true understanding of how complement activation and 
homeostasis are regulated.
Materials and Methods
Protein reagents and antibodies. For plate assay experiments, commercial preparations of full-length 
FH and CRP, both purified from pooled human plasma (Sigma-Aldrich, Poole, UK), were used. Recombinant 
factor H proteins, i.e. FHL-1 (402Y and 402H variants), CCP6-8 (402Y/402YH) and CCP67 (402Y/402H ± tail) 
were made in-house using previously published protocols7,33. Human PTX3 was expressed in PerC6 cells and 
purified as described previously62, and was subject to buffer-exchange (10 mM Tris, 150 mM NaCl pH 7.5) by size 
exclusion chromatography with multiple angle laser light scattering (SEC-MALLS) before use; this verified that 
the protein used was octameric48. In plate assays, the murine OX23 monoclonal antibody (Abcam, Cambridge, 
United Kingdom) was used to detect FH binding while a rabbit polyclonal antiserum was raised against a peptide 
from CCP7 of FH/FHL-1 (H-CGYNQNHGRKFV-NH2 coupled to Diphtheria Toxoid as the carrier protein) by 
Mimotopes (Clayton, Australia) and used to detect the recombinant factor H proteins (i.e. FHL-1, CCP6-8 and 
CCP67 ± tail); in control experiments the polyclonal was demonstrated to have identical binding to the 402H and 
402Y variants. In plate assays, bound PTX3 was detected using a rabbit polyclonal antibody63.
For the fluorescent staining of human donor eye tissue, endogenous CRP was detected with a rabbit anti-CRP 
polyclonal antibody (cat. No. 235752; Calbiochem, Watford, UK), which does not distinguish mCRP from pCRP, 
and PTX3 was visualized using the same anti-PTX3 polyclonal antibody as described above. In both cases bound 
primary antibody was detected with an AlexaFluor488 conjugated goat anti-rabbit antibody (Life Technologies, 
Paisley, UK).
SDS-PAGE. The recombinantly expressed proteins (i.e. FHL-1, CCP67 and CCP67± tail proteins) were 
assessed by SDS-PAGE to confirm they were of the expected size, purity and concentration (see Supplemental 
Figures S1 and S3). Two micrograms of protein were loaded and samples were run on 4–12% BisTris NuPAGE 
gels (ThermoScientific, Loughborough, UK) under reducing conditions. Blue Protein Standard Broad Range 
(New England Biolabs, Hitchin, UK) was used as a protein marker. Gels were stained using Coomassie Instant 
Blue (Expedeon, Swavesey, UK) for 1 hour at room temperature before being destained in miliQ water and 
photographed.
Microtiter plate assays. CRP binding assays. CRP binding assays were adapted from published meth-
ods20. CRP (Sigma) was immobilized on Nunc-Immuno MaxiSorp F96-well plates (ThermoScientific) at 0.5 µg/
well in Coating-Binding-Blocking (CBB) buffer (50 mM HEPES, 100 mM NaCl, pH 7.4) and coated overnight at 
4 °C. Blank wells were coated with CBB buffer without protein. Since CRP dissociates from its pentameric form 
into monomers in the absence of calcium64,65, we immobilized CRP in both presence and absence of calcium 
to generate either pCRP or mCRP; moreover, for the experiments with pCRP, we included 2 mM CaCl2 in our 
CBB buffer. Between all steps plates were washed and dried three times in washing buffer (CBB buffer with 0.1% 
www.nature.com/scientificreports/
9SCiENTiFiC RePoRTs |  (2018) 8:1643  | DOI:10.1038/s41598-017-18395-7
(v/v) Tween-20, pH 7.5). Following coating, plates were then blocked in 5% (w/v) BSA (Sigma) in CBB buffer 
for 1 hour at room temperature. FH/FHL-1 proteins were added in fluid phase at varying concentrations in CBB 
buffer for 2 hours at room temperature and bound protein was detected with the primary antibodies described 
above. Subsequently, either goat anti-mouse (against OX23) or goat anti-rabbit (against anti-CCP7) IgG coupled 
to alkaline phosphatase (Sigma) were added and incubated for 30 minutes. All primary and secondary antibodies/
antisera, were added at a 1:2000 dilution in CBB buffer. Finally, 1 mg/ml p-nitrophenyl phosphate SigmaFast™ 
substrate (Sigma) was added to all wells and signals were measured at 405 nm (after appropriate development 
times) on a SpectraMax 340PC384 Microplate Reader (Molecular Devices, Sunnyvale, United States). Blank well 
values were subtracted from those from sample wells, where mean values from an average of two or three separate 
experiments were determined ± SEM.
Competition assays were also performed to determine if FHL-1 is able to compete for the binding of FH 
to mCRP. Here the assays were performed as described above but where the FH was kept constant (30 mM) 
being incubated with varying concentrations of FHL-1 (i.e. 4.7, 9.4, 18.8, 37.5, 75, 150, and 300 mM) for 30 min 
at room temperature before application to immobilized mCRP. Bound FH was subsequently detected with a 
goat anti-mouse monoclonal antibody against the C-terminal CCP20 domain of FH (clone L20/3, Cambridge 
Biosciences, Cambridge, UK) used at a dilution of 1:1000. Similarly, in competition assays where PTX3 com-
petes for FHL-1 binding to mCRP, FHL-1 was kept constant at 50 mM and increasing PTX-3 concentrations (i.e. 
7.8, 15.6, 31.25, 62.5, 128, 250, and 500 mM) were used. Bound FHL-1 was detected with the OX23 antibody as 
described above.
PTX3 binding assays. PTX3 binding assays were carried out according to established protocols; in contrast 
to CRP assays, PTX3 was added in the solution phase. Varying concentrations of full-length FH, FHL-1, CCP6-8 
and CCP67 ± tail proteins were coated on plates in PBS+/+ (PBS containing 0.90 mM CaCl2 and 0.49 mM MgCl2) 
overnight at 4 °C. Blank wells were coated with PBS+/+ without protein. Plates were blocked in 1% (w/v) BSA 
(Sigma) in wash buffer (20 mM TrisHCl, 150 mM NaCl, 1 mM MgCl2, 1 mM CaCl2, 0.1% (v/v) Tween-20, pH 7.0) 
for 2 hours at 37 °C. PTX3 was added in solution phase at 0.1 µg/well in wash buffer for 1 hour at 37 °C. Anti-PTX3 
polyclonal antibody (diluted 1:10,000 in wash buffer) and subsequently goat anti-rabbit IgG coupled to alkaline 
phosphatase (Sigma-Aldrich; 1:2,000 dilution in wash buffer) was used to detect bound PTX3. Antibodies were 
incubated for 60 minutes at 37 °C. The plates were developed and read as described above. Between all steps plates 
were washed and dried three times in washing buffer.
Donor Eye Tissue. Post-mortem donor eyes were obtained from the Manchester Eye Bank at the Royal Eye 
Hospital (Manchester, UK), within 48 hours from the time of death, after removal of the corneas for transplanta-
tion; these were classified and curated as part of the Manchester Eye Tissue Repository (ETR). No organs/tissues 
were procured from prisoners. Our research adhered to the tenets of the Declaration of Helsinki and in all cases, 
there was prior informed consent for the eye tissue to be used for research obtained and held by the Manchester 
Eye Bank, and guidelines established in the Human Tissue Act of 2004 (UK) were followed. Ethical approval for 
the use of tissue in these experiments was granted by the Manchester Eye Tissue Repository ethics committee 
(ref.15/NW/0932). Except in the case of AMD tissues (see below), none of the other donors had a history of visual 
impairment or eye disease; see Supplementary Table 1. Post mortem times for non-AMD and AMD donor tissue 
were similar with an average of 40 hours (range 28–48 h) and an average 37 hours (range 26–48 h) respectively. 
Six millimeter diameter punch biopsies were taken from the macula region of the retinas, and then fixed in 4% 
(v/v) paraformaldehyde for 1 hour, before being stored in OCT embedding matrix (Cell Path Ltd, Wales, UK) at 
−80 °C. All donor eyes were classified as AMD or non-AMD based on the presence of clinically sized drusen in 
the macula in post-mortem fundus images, which is carried out routinely within the Manchester ETR.
Sample genotyping. DNA isolation. DNA was isolated from iris/ciliary body tissue dissected from 
post-mortem human donor eyes, using the Qiagen BioRobot® EZ1 and the EZ1 Advanced XL DNA Tissue Card 
(Qiagen, Crawley, UK). All samples were normalized to a concentration of 20 ng/μl for Sequenom analysis.
Assay design/SNP selection. A Sequenom assay was designed against potential SNPs implicated in AMD (i.e. 
CFH Y402H: rs1061170; CFHR1-3 deletion: rs7542235; ARMS2/HTRA1: rs10490924). Primers were designed 
using Sequenom SNP Assay Design software version 3.0 for iPLEX reactions. The protocol and reaction condi-
tions were in accordance with the manufacturer.
Genotyping and Sanger sequencing. Genotype identification was performed with the MassARRAY system from 
Sequenom. The MALDI-TOF MS spectra from the Sequenom MassARRAY® Analyzer 4 instrument were ana-
lyzed using Typer 4.0.20 software (Sequenom, San Diego, USA). Automated fluorescent cycle DNA sequencing66 
was performed using an Applied Biosystems model 3730 DNA analyzer. STADEN67 package Pregap4 1.4b1 soft-
ware Version 1.8b1 (Medical Research Council, Laboratory of Molecular Biology, UK) were used for analysis of 
sequencing.
Tissue sectioning. Macula tissues were sectioned with a Leica CM1950 cryostat (Leica Biosystems, 
Peterborough, UK) as described previously10. Briefly, sections were mounted with OCT embedding matrix (Cell 
Path Ltd, Wales, UK) onto pre-cooled chucks in the cryostat. The cryostat was kept at −18 °C, and 10 µm thick 
sections were made with a microtome blade (MX35 Premier Plus 34°/80 mm, Thermo Fisher Scientific, Waltham, 
MA, USA). Sections were mounted onto slides (X-tra Adhesive Clipped Corner Slides, Leica Biosystems, 
Peterborough, UK) and stored at −80 °C.
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Fluorescence immunohistochemistry. Tissue sections were prepared from the macular region as 
described above; see list of human donors in Supplementary Table 1. For CRP staining, five early AMD donors 
(average age = 74) were compared to six non-AMD donors (average age = 74). For PTX3 staining, eighteen early 
AMD donors (average age = 78) were compared to eighteen age-matched non-AMD donors (average age = 77). 
Immunofluorescent staining of eye sections was performed as previously published7,10. Briefly, slides were first 
incubated with chilled 50% (v/v) acetone, 50% (v/v) methanol (−20 °C) for 20 seconds. Slides were then washed 
thoroughly with PBS: all subsequent wash steps were performed at room temperature with PBS. Slides were 
then blocked by incubation with blocking solution (1 mg/ml BSA (Sigma), 1% (v/v) goat serum (Sigma), 0.1% 
(v/v) Triton X-100 (Sigma) in PBS) for 1 hour at room temperature. After thorough washing, primary antibodies 
against CRP (1:1000 in PBS) and PTX3 (1:10,000 in PBS) were added overnight at 4 °C. Slides were washed as 
above before the addition of the AlexaFlour488-conjugated secondary antibody for 2 hours at room temperature 
at a final concentration of 2 µg/ml in PBS. Sections were included where only secondary antibody was added as 
‘blank’ controls. After a final wash with PBS, DAPI (Sigma-Aldrich; 1 µg/ml in PBS) was added and incubated 
for 5 min. Vectorshield (Vector Labs, Peterborough, UK) was added to preserve stained tissues before adding a 
coverslip. Slides were stored in the dark at 4 °C.
Equipment and settings. All images were collected on an Olympus BX51 upright microscope using a 20x objec-
tive and captured using a Coolsnap ES camera (Photometrics) through MetaVue Software (Molecular Devices). 
Specific band pass filter sets for DAPI and FITC were used to prevent bleed through from one channel to the next. 
All LUTs are linear and cover the full range of data. Images were acquired at 8-bit resolution and analyzed using 
ImageJ64 (version 1.40 g; rsb.info.nih.gov/ij).
Fluorescence intensity measurements. For the quantitation of PTX3 staining in AMD and non-AMD donor eye 
tissue, previously described protocols were followed10. Briefly, gray scale images for both blank and stained sec-
tions for each donor were used for the measurement of relative fluorescent levels. Either the whole macula tissue 
(minus any RPE cells present) or just the choriocapillaris/Bruch’s membrane was selected using the selection tools 
in imageJ64. Between two and four separate fields of view per section were measured and averaged to determine 
a representative value for each donor. The final value obtained for the blank sections was subtracted from the 
value obtained for the respective test section to correct for the influence of donor-to-donor variance in tissue 
auto-fluorescence. Data were plotted and analyzed using GraphPad Prism (Version 6.04, GraphPad Software 
Inc.).
Statistical analysis. Student’s T-tests were performed on solid phase binding assay data and a p-value <0.05 
was considered significant; in addition, two-way ANOVA analysis was performed to analyze the binding of PTX3 
to immobilized 402Y or 402 H variants of FHL-1. One-way ANOVA analysis was performed on PTX3 fluorescent 
staining intensities, where a p-value < 0.05 was considered significant.
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